Literature DB >> 24691893

Use of aspirin, non-steroidal anti-inflammatory drugs, and acetaminophen (paracetamol), and risk of psoriasis and psoriatic arthritis: a cohort study.

Shaowei Wu1, Jiali Han, Abrar A Qureshi.   

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) have been reported to induce or exacerbate psoriasis. We aimed to evaluate the association between several widely used analgesics, including aspirin, non-aspirin NSAIDs, and acetaminophen (paracetamol), and risk of psoriasis and psoriatic arthritis (PsA) in a large cohort of US women, the Nurses' Health Study II (1991-2005). Information on regular use of aspirin, NSAIDs, and acetaminophen was collected for 95,540 participants during the follow-up. During 1,321,280 person-years of follow-up, we documented 646 incident psoriasis cases and 165 concomitant PsA cases. Compared to women who reported no use, regular acetaminophen and NSAIDs users with more than 10 years of use had multivariate hazard ratios of 3.60 [95% confidence interval (CI): 2.02-6.41] and 2.10 (95% CI: 1.11-3.96) for PsA, respectively. There was no clear association between aspirin and risk of psoriasis or PsA. In conclusion, long-term acetaminophen and NSAIDs use may be associated with an increased risk of PsA. Special attention on psoriasis and PsA screening may be needed for those who are prescribed for acetaminophen and NSAIDs for long-term periods.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24691893      PMCID: PMC4183729          DOI: 10.2340/00015555-1855

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  48 in total

Review 1.  NSAIDs in dermatologic therapy: review and preview.

Authors:  Edward S Friedman; Nicole LaNatra; Matthew J Stiller
Journal:  J Cutan Med Surg       Date:  2002-09-04       Impact factor: 2.092

2.  A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis.

Authors:  C Salvarani; P Macchioni; I Olivieri; A Marchesoni; M Cutolo; G Ferraccioli; F Cantini; F Salaffi; A Padula; C Lovino; L Dovigo; G Bordin; C Davoli; G Pasero; O D Alberighi
Journal:  J Rheumatol       Date:  2001-10       Impact factor: 4.666

3.  Psoriasis associated with rofecoxib.

Authors:  David Walter John Clark; David Morris Coulter
Journal:  Arch Dermatol       Date:  2003-09

4.  Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women.

Authors:  Shaowei Wu; Wen-Qing Li; Jiali Han; Qi Sun; Abrar A Qureshi
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

Review 5.  Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs).

Authors:  K D Rainsford
Journal:  Am J Med       Date:  1999-12-13       Impact factor: 4.965

6.  Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis.

Authors:  V M Yates; G Watkinson; A Kelman
Journal:  Br J Dermatol       Date:  1982-03       Impact factor: 9.302

Review 7.  Pathogenesis of psoriatic arthritis.

Authors:  U Fearon; D J Veale
Journal:  Clin Exp Dermatol       Date:  2001-06       Impact factor: 3.470

8.  The effects of non-steroid anti-inflammatory drugs on leukocyte migration in carrageenin-induced inflammation.

Authors:  G A Higgs; K E Eakins; K G Mugridge; S Moncada; J R Vane
Journal:  Eur J Pharmacol       Date:  1980-08-22       Impact factor: 4.432

Review 9.  Connections between psoriasis and Crohn's disease.

Authors:  David James Najarian; Alice B Gottlieb
Journal:  J Am Acad Dermatol       Date:  2003-06       Impact factor: 11.527

10.  The direct cost of care for psoriasis and psoriatic arthritis in the United States.

Authors:  Harold S Javitz; Marcia M Ward; Eugene Farber; Lexie Nail; Susan Gillis Vallow
Journal:  J Am Acad Dermatol       Date:  2002-06       Impact factor: 11.527

View more
  7 in total

1.  Research Resource: A Reference Transcriptome for Constitutive Androstane Receptor and Pregnane X Receptor Xenobiotic Signaling.

Authors:  Scott A Ochsner; Anna Tsimelzon; Jianrong Dong; Cristian Coarfa; Neil J McKenna
Journal:  Mol Endocrinol       Date:  2016-07-13

Review 2.  Clinical Risk Factors for the Development of Psoriatic Arthritis Among Patients with Psoriasis: A Review of Available Evidence.

Authors:  Alexis Ogdie; J M Gelfand
Journal:  Curr Rheumatol Rep       Date:  2015-10       Impact factor: 4.592

Review 3.  Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time.

Authors:  Eva Klara Merzel Šabović; Mateja Starbek Zorko; Miodrag Janić
Journal:  Int J Mol Sci       Date:  2022-06-14       Impact factor: 6.208

4.  Super Critical Fluid Extracted Fatty Acids from Withania somnifera Seeds Repair Psoriasis-Like Skin Lesions and Attenuate Pro-Inflammatory Cytokines (TNF-α and IL-6) Release.

Authors:  Acharya Balkrishna; Pradeep Nain; Anshul Chauhan; Niti Sharma; Abhishek Gupta; Ravikant Ranjan; Anurag Varshney
Journal:  Biomolecules       Date:  2020-01-25

Review 5.  Psoriasis and Cardiovascular Risk: A Comprehensive Review.

Authors:  Walter Masson; Martín Lobo; Graciela Molinero
Journal:  Adv Ther       Date:  2020-04-20       Impact factor: 3.845

6.  Resolvin E1 attenuates murine psoriatic dermatitis.

Authors:  Yu Sawada; Tetsuya Honda; Satoshi Nakamizo; Atsushi Otsuka; Narihito Ogawa; Yuichi Kobayashi; Motonobu Nakamura; Kenji Kabashima
Journal:  Sci Rep       Date:  2018-08-08       Impact factor: 4.379

7.  cPLA2α Enzyme Inhibition Attenuates Inflammation and Keratinocyte Proliferation.

Authors:  Felicity J Ashcroft; Nur Mahammad; Helene Midtun Flatekvål; Astrid Jullumstrø Feuerherm; Berit Johansen
Journal:  Biomolecules       Date:  2020-10-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.